- Current languageen
Pharmaceuticals - Union Register
Union Register of medicinal products for human use
|Auth. number :||EU/1/18/1333|
|Active substance :||doravirine / lamivudine / tenofovir disoproxil|
|ATC:||Anatomical main group: J - General antiinfectives for systemic use|
Therapeutic subgroup: J05 - Antivirals for systemic use
Pharmacological subgroup: J05A - Agents affecting the virus directly
Chemical subgroup: J05AR - Antivirals for treatment of hiv infections, combinations
Chemical substance: J05AR24 - lamivudine, tenofovir disoproxil and doravirine
(See WHO ATC Index)
|Indication:||Delstrigo is indicated for the treatment of adults infected with HIV 1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir|
|Marketing Authorisation Holder:||Merck Sharp & Dohme B.V.
Waarderweg 39, 2031 BN Haarlem, Nederland
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Union Register.